Purpose of the study. To assess the effectiveness of the use of hemostatic agent "GEMOGUBKA" for the prevention of bleeding from the bed of the gallbladder during traditional cholecystectomy. Methods. The study included 88 patients operated for acute calculous cholecystitis. Depending on the method of bleeding hemostasis, all patients were divided into 2 groups: in the study group (n=43), after cholecystectomy, 250-300 mg of "GEMOGUBKA" in the form of a fine powder was applied to the gallbladder bed for hemostasis; in the control group (n=45), after cholecystectomy, hemostasis was carried out by electrocoagulation of the gallbladder bed with a monopolar electrode. All patients in the postoperative period underwent control-dynamic ultrasound examination, study of the volume and nature of the discharge from the drains, as well as a biochemical blood tests. Results. In the study group, the average duration of hemostasis with bleeding from the bladder bed was 2,3±1,3 minutes, which is almost 2 times less than in the control group - 4,2±1,5 minutes. The duration of bed-days after surgery was 4,5±0,78 days and 6,3±2,06 days, respectively. The duration of the presence of the drainage tubes in the abdominal cavity in the study group was 1,49±0,88 days, while in the control group it was 4,24±1,38 days. The dynamics of the manifestation of cytolytic syndrome showed a low degree of intraoperative aggression during hemostasis in the study group, which significantly differed from the high rates of cytolysis in the control group. In the study group of patients, it was possible to significantly reduce the proportion of serous-hemorrhagic and hemorrhagic discharge from the drainage tube in comparison with patients in the control group. Conclusion. The use of the biocomposition in the form of the hemostatic drug "GEMOGUBKA" allowed both to reduce the duration of bleeding from the bed of the gallbladder, and the incidence of local inflammatory complications of the surgical site during traditional cholecystectomy.
